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論文の内容の要旨 
Abstract of thesis 
In this doctoral dissertation, XIAFUKAITI GULIBAIKELAMU describes the phenotypes of pancreatic beta 
cell-specific MAFA and MAFB double KO.  The content is summarized as follows:  
（目的 Purpose） 
The author’s laboratory has been investigating MAF family.  Her project focused on the role of MAFB in relation 
to MAFA.  Lifelong expression of MAFB in human pancreatic β-cells implies its involvement in maintaining 
mature β-cell function. Despite being a preferred mammalian model for biomedical research, mice do not express 
MafB in adult pancreatic β-cells. Interestingly, re-expression of MafB in the β-cells of adult MafA deficient mice 
was detected in the previous study, which implies potential role of MafB in mature β-cells under certain 
pathological condition in mice. Therefore, the purpose of this study was to investigate whether MafB can take part 






（対象と方法 Materials and Methods） 
Using C57BL/6J mice strain, the author generated MafA and MafB double knockout (A0B0) mice in which MafB 
was specifically deleted from the pancreatic β-cells, and compared their phenotype with those of MafA single 
knockout (A0B2) and WT mice under normal diet and high fat diet (HFD) conditions. To compare the glucose 
metabolism of each mice group, fasting blood glucose level measurement, i.p. glucose tolerance test and glucose 
stimulated insulin secretion experiments were conducted at certain time points. To compare the islet morphology of 
the mice from different genotypes, immunohistochemistry and hematoxylin and eosin staining were performed 
together with the cell counting. Quantitative real-time PCR experiment was also done using islet derived cDNA to 
check gene expression.   
 
（結果 Results） 
The author observed that additional deletion of MafB aggravated the metabolic phenotype resulting from MafA 
single knockout mice. Under a normal diet condition, relatively more impaired glucose intolerance in A0B0 mice 
than A0B2 mice was observed. Sheconsidered that impaired glucose tolerance could be due to either the impaired 
insulin production and thus impaired insulin content, or reduced insulin secretion in response to an elevated blood 
glucose level. However, she observed that neither the whole pancreatic insulin content nor the glucose stimulated 
insulin secretion showed significant differences between the A0B2 and A0B0 mice. In contrast, the α-cell to β-cell 
ratio and double positive cells became remarkably higher in the A0B0 islets compared to the A0B2 islets, and she 
assumed that this abnormal α-cell/β-cell relationship could explain the relatively more impaired glucose tolerance 
in A0B0 mice than in A0B2 mice under normal diet conditions.   
Based upon the above data, the author considered that on a C57BL/6J background under a normal diet, a deficiency 
of MafA alone was not sufficient to present the possible role of MafB in maintaining adult β-cell function. 
Therefore, she next implemented HFD treatment for mice, and observed drastic reduction in insulin positive cell 
numbers and severely impaired glucose tolerance together with symptoms of diabetes in A0B0 mice, while glucose 
stimulated insulin secretion showed no difference between A0B0 and A0B2 mice, indicating that critically damaged 
insulin production ability of β-cells can be thereason for A0B0 mice to become extremely glucose intolerant and 
develop diabetes. In addition to that, she observed total islet numbers were notably reduced and islet size failed to 
properly expand in the A0B0 pancreas.  
 
（考察 Discussion） 
Based on these observations, the author proposed that in insulin resistance disorders caused by obesity or gestation, 
the β-cell mass increases to adapt to the body’s increased requirements for insulin, which results in enlarged islets 
and increased islet numbers, and thatdeficiency of MafA in an HFD condition is harmful enough to cause insulin 
insensitivity in the body. The author speculated that removing MafB from β-cells will further inhibit the β-cell mass 
from expending itself by increasing the islet number and islet size. 
 
（結論 Conclusions） 




islet morphology and decreased insulin-expressing cell numbers, indicatingthat MafB plays as cryptic, but an 
important factor for adult pancreatic β-cell formation, unmasked under a MafA deficient condition in mice. She 
claims that this is the first study to show role of MafB in mature pancreatic β-cells in a certain pathological state 
using MafA and MafB double knock-out mouse in the β-cells, and that this finding can be appliedtohumans not 
only to understand type2 diabetes disease process, but also to provide MafB as a possible target for diabetic 
diseasetreatment. 
審査の結果の要旨 
Abstract of assessment result 
（批評 General Comments） 
This study is carefully designed based upon the previous report that MafB expression was induced in proliferative 
β-cell of the pregnant and HFD treated mice. Theauthor’s main observations are as follow. First, A0B0 adult mice 
displayed more severely impaired glucose tolerance compared to A0B2 mice. This phenomenon was further 
aggravated on HFD, which caused diabetes in the A0B0 mice. Second, deficiency of MafA has a destructive effect 
on normal islet structure, and moreover, this abnormality becomes more severe with the deletion of MafB. Third, a 
notable reduction in islets and islet cell numbers together with unsuccessful expansion of islet size was detected in 
HFD feeding A0B0 mice. The author’s findings suggest that MAFB could be a potential molecular targeted therapy 




The final examination committee conducted a meeting as a final examination on July3, 2019. The applicant 
provided an overview of dissertation, addressed questions and comments raised during Q&A session. All of the 
committee members reached a final decision that the applicant has passed the final examination. 
 
（結論 Conclusion） 
The final examination committee approved that the applicant is qualified to be awarded Doctor of Philosophy in 
Medical Sciences. 
 
